In contrast, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II (Ang II) receptor type I blockers have been used for a long time to prevent endothelial dysfunction in T2DM patients. The gene discussed is ACE; the disease is type 2 diabetes mellitus.